
|Articles|October 10, 2012
Two-drug combination best for melanoma
A two-drug combination for metastatic melanoma reduced the odds of progression by 60 percent, demonstrating more effectiveness than monotherapy, according to researchers.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Next-Generation IL-4Rα Targeting and Potential Dermatologic Implications
2
Comparative Analysis Positions Zasocitinib Among Next-Generation TYK2 Inhibitors
3
Utilizing CYP2C9 Testing and JAK Inhibitors for Alopecia Areata
4
Timing, Severity, and Therapeutic Choice in Moderate to Severe HS
5


















